Arialys Therapeutics, a private biotech company founded by Avalon BioVentures, Catalys Pacific, and MPM Capital, is exploring scientific breakthroughs in autoimmune neurology to develop new precision medicines for autoimmune neurological and neuropsychiatric diseases. Our lead therapeutic candidate, ART5803, is being developed as a potential treatment for anti-NMDA receptor encephalitis (ANRE), a life-threatening neurological disease that causes severe psychosis. ART5803 also has potential to treat autoimmune dementia. The Arialys team has decades of experience identifying biomedical research innovations with the potential to address significant unmet medical needs and building novel therapeutics to bring to the clinic.